<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539317</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 7630</org_study_id>
    <nct_id>NCT01539317</nct_id>
  </id_info>
  <brief_title>Therapy to Prevent Sexual Pain in Breast Cancer Survivors</brief_title>
  <official_title>Therapy to Prevent Sexual Pain in Menopausal Survivors of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to determine whether pain with sexual intercourse can be
      reduced in menopausal, breast cancer survivors and to evaluate the effectiveness of a
      non-hormonal therapy (Lidocaine Liquid) vs. a placebo liquid in reducing pain.

      The investigators hypothesize that the pain arises in the vulvar vestibule. The investigators
      predict that the localized use of lidocaine will be more efficacious than use of placebo
      liquid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this study there will be three visits over a 3 month period. Subjects will undergo a
      gynecological exam at the screening visit to determine the severity of pain associated with
      uncomfortable intercourse. A touch test using Q-tips will be used during screening exam so
      subjects can report pain during application of both study drug and placebo. Subjects will
      also report pain during tampon test. A sample of vaginal cells and liquid will be obtained at
      screening visit so that PI can rule out possible infection, disease, or disorders. PI will
      also show subject the area of the vestibule in a mirror so that subject can apply study drug
      at home properly. Subjects will fill out 4 questionnaires about medical and health history,
      cancer history, pain, and distress and sexual activity. Subject will be given a supply of
      either study drug or placebo to take home. The first visit will last approximately 2 hours.

      Subjects will return for a second visit after 4 weeks and a third visit after 8 weeks for
      diary review, questionnaires, and examination. The second and third visit examinations will
      be repeats of the examination done at the first visit, but there will be no comparison with
      placebo, the PI will use only study drug during the touch test. The second and third visits
      will last approximately 1 hour.

      Subjects will fill out questionnaires throughout study participation. Topics include; medical
      and health history, cancer history, pain, distress and sexual activity. Subjects will also
      fill out a diary that charts tampon test completed from home, sexual activity performed, pain
      levels and study drug application days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of Entry Dyspareunia With Non-hormonal Therapy</measure>
    <time_frame>During Phase II (0-4 weeks) and during Phase III (5-12 weeks)</time_frame>
    <description>Mean intercourse pain reported by subjects using the Numerical Rating Scale pain ratings (range 0-10, 0 being &quot;no pain&quot; and 10 being &quot;worst possible pain&quot;). Testing was during weeks 0-4 (Phase II) (with blinded randomization for placebo vs active intervention medication) and testing was during weeks 5-12 (Phase III) (with open-label active medication for 8 weeks after completing the blinded 4 weeks). Subjects agreed to try penetration twice per week and score their pain using the Numerical Rating Scale pain ratings.The scores were averaged during each phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Location of Pain in Postmenopausal Dyspareunia</measure>
    <time_frame>Enrollment visit</time_frame>
    <description>To determine the specific site of vulvovaginal tenderness in menopausal breast cancer survivors who have entry dyspareunia. Examine the vulvar vestibule with a swab test to determine locations and severity of touch tenderness. Eight sites were evaluated around the vaginal opening and there location was in reference to a clock face. Measured using the Numerical Rating Scale, a scale which measures pain from 0 to 10 with 0=&quot;no pain&quot; and 10=&quot;the worst pain you have ever felt&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Quality of Sexual Life - Visit 1</measure>
    <time_frame>Visit 1 (Enrollment)</time_frame>
    <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by average scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Quality of Sexual Life - Visit 2</measure>
    <time_frame>Visit 2 (Week 4)</time_frame>
    <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by averaged scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Quality of Sexual Life - Visit 3</measure>
    <time_frame>Visit 3 (End of Study)</time_frame>
    <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by average scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Vulvodynia</condition>
  <condition>Dyspareunia</condition>
  <condition>Breast Cancer</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Topical liquid lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical liquid lidocaine</intervention_name>
    <description>active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule</description>
    <arm_group_label>Topical liquid lidocaine</arm_group_label>
    <arm_group_label>Topical Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical saline</intervention_name>
    <description>saline applied to the vestibule mucosa will not reverse the local tenderness</description>
    <arm_group_label>Topical liquid lidocaine</arm_group_label>
    <arm_group_label>Topical Saline</arm_group_label>
    <other_name>water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria

          1. Women aged 18 to 70 years old.

          2. Has a previous diagnosis of breast cancer (ductal or lobular carcinoma, invasive).

          3. 1 year from diagnosis of breast cancer.

          4. Stable heterosexual partnership =/&gt;5 years or by investigator discretion.

          5. More than 6 months of consistent insertional pain with intercourse (may have stopped
             having intercourse due to this consistent experience of pain).

          6. Menopausal, demonstrated by at least one of the following:

             i. cessation of menses for 1 years ii. Bilateral oophorectomy iii. Follicle
             Stimulating Hormone (FSH) level &gt;25 in women below age 50 with an ovary and scarred or
             absent uterus (acceptable FSH levels can be inferred if the woman's oncologist
             monitors FSH during aromatase inhibitor therapy).

          7. Willingness to enter a study comparing a topical placebo liquid to topical liquid
             lidocaine.

          8. Willingness to evaluate the liquids by use of a tampon test as many as 4 times per
             month, and willingness to attempt intercourse if the tampon test indicates tolerable
             penetrative pain.

        3.2 Exclusion Criteria

          1. Diagnosis of benign or malignant phyllodes tumor of the breast.

          2. Consistently has pain in the pelvis or low abdomen during or after intercourse (deep
             dyspareunia).

          3. Has developed shrinkage of the vaginal opening or vaginal length to the point of being
             too small to succeed in having vaginal penetration with the partner (will also be
             assessed at the clinical exam).

          4. Partner has a problem of sexual dysfunction limiting his performance or making it
             inconsistent.

          5. The potential subject or her partner has a serious current medical condition that
             might interrupt completion of a 6 month study.

          6. Potential subject has been diagnosed by a physical therapist with significant pelvic
             floor muscle dysfunction causing pain (pelvic floor myalgia).

          7. Potential subject has used topical or systemic estrogen within the last 4 months.

          8. Has continued tenderness of vestibule mucosa immediately after application of both
             test liquids.

          9. Allergy to lidocaine or other numbing agents.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha Goetsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ohsu.edu/xd/health/services/women/clinical-trials</url>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <results_first_submitted>June 5, 2015</results_first_submitted>
  <results_first_submitted_qc>July 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2015</results_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Martha Goetsch</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Vulvodynia</keyword>
  <keyword>Dyspareunia</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Menopause</keyword>
  <keyword>Vaginal dryness</keyword>
  <keyword>Painful intercourse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vulvodynia</mesh_term>
    <mesh_term>Dyspareunia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>January 2012 to June 2013; Women’s Health Research Unit (WHRU) at Oregon Health and Science University (OHSU) in Portland, OR</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Topical Liquid Lidocaine</title>
          <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
        </group>
        <group group_id="P2">
          <title>Topical Saline</title>
          <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screening Error. Deleted from analysis.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topical Liquid Lidocaine</title>
          <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
        </group>
        <group group_id="B2">
          <title>Topical Saline</title>
          <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="8.5"/>
                    <measurement group_id="B2" value="54.7" spread="8.9"/>
                    <measurement group_id="B3" value="55.34" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevention of Entry Dyspareunia With Non-hormonal Therapy</title>
        <description>Mean intercourse pain reported by subjects using the Numerical Rating Scale pain ratings (range 0-10, 0 being &quot;no pain&quot; and 10 being &quot;worst possible pain&quot;). Testing was during weeks 0-4 (Phase II) (with blinded randomization for placebo vs active intervention medication) and testing was during weeks 5-12 (Phase III) (with open-label active medication for 8 weeks after completing the blinded 4 weeks). Subjects agreed to try penetration twice per week and score their pain using the Numerical Rating Scale pain ratings.The scores were averaged during each phase.</description>
        <time_frame>During Phase II (0-4 weeks) and during Phase III (5-12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Saline</title>
            <description>Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness</description>
          </group>
          <group group_id="O2">
            <title>Topical Liquid Lidocaine</title>
            <description>Topical liquid lidocaine: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
Topical saline: saline applied to the vestibule mucosa will not reverse the local tenderness</description>
          </group>
          <group group_id="O3">
            <title>Open Label</title>
            <description>During Open-label Lidocaine 8 weeks
Each prior arm converted to use of open label lidocaine for 2 further months.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevention of Entry Dyspareunia With Non-hormonal Therapy</title>
          <description>Mean intercourse pain reported by subjects using the Numerical Rating Scale pain ratings (range 0-10, 0 being &quot;no pain&quot; and 10 being &quot;worst possible pain&quot;). Testing was during weeks 0-4 (Phase II) (with blinded randomization for placebo vs active intervention medication) and testing was during weeks 5-12 (Phase III) (with open-label active medication for 8 weeks after completing the blinded 4 weeks). Subjects agreed to try penetration twice per week and score their pain using the Numerical Rating Scale pain ratings.The scores were averaged during each phase.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.65" upper_limit="1.92"/>
                    <measurement group_id="O3" value="NA">Phase II was not the open label portion of the study</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.07" upper_limit="1.80"/>
                    <measurement group_id="O2" value="0.45" lower_limit="0" upper_limit="1.14"/>
                    <measurement group_id="O3" value="0.48" lower_limit="0" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phase II: During Blinded 4 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0149</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Phase III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.412</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Quality of Sexual Life - Visit 1</title>
        <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by average scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
        <time_frame>Visit 1 (Enrollment)</time_frame>
        <population>Averaged scores of Sexual Function Questionnaire Visit 1 each time scoring from the prior 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Saline</title>
            <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
          </group>
          <group group_id="O2">
            <title>Topical Liquid Lidocaine</title>
            <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Quality of Sexual Life - Visit 1</title>
          <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by average scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
          <population>Averaged scores of Sexual Function Questionnaire Visit 1 each time scoring from the prior 30 days.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Desire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.91" lower_limit="9" upper_limit="14"/>
                    <measurement group_id="O2" value="13.87" lower_limit="12" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="O2" value="9.15" lower_limit="8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Lubrication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="2.97" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Cognitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O2" value="4.82" lower_limit="4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="7.62" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" lower_limit="4.48" upper_limit="8"/>
                    <measurement group_id="O2" value="6.29" lower_limit="5" upper_limit="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.30" lower_limit="12" upper_limit="17.68"/>
                    <measurement group_id="O2" value="17.01" lower_limit="14" upper_limit="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O2" value="8.13" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Desire</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arousal (S)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arousal (L)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arousal (C)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Orgasm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Enjoyment</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Partner</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Location of Pain in Postmenopausal Dyspareunia</title>
        <description>To determine the specific site of vulvovaginal tenderness in menopausal breast cancer survivors who have entry dyspareunia. Examine the vulvar vestibule with a swab test to determine locations and severity of touch tenderness. Eight sites were evaluated around the vaginal opening and there location was in reference to a clock face. Measured using the Numerical Rating Scale, a scale which measures pain from 0 to 10 with 0=&quot;no pain&quot; and 10=&quot;the worst pain you have ever felt&quot;.</description>
        <time_frame>Enrollment visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Saline</title>
            <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
          </group>
          <group group_id="O2">
            <title>Topical Liquid Lidocaine</title>
            <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
          </group>
        </group_list>
        <measure>
          <title>Location of Pain in Postmenopausal Dyspareunia</title>
          <description>To determine the specific site of vulvovaginal tenderness in menopausal breast cancer survivors who have entry dyspareunia. Examine the vulvar vestibule with a swab test to determine locations and severity of touch tenderness. Eight sites were evaluated around the vaginal opening and there location was in reference to a clock face. Measured using the Numerical Rating Scale, a scale which measures pain from 0 to 10 with 0=&quot;no pain&quot; and 10=&quot;the worst pain you have ever felt&quot;.</description>
          <units>units on a scale from 0 to 10</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 o'clock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 o'clock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 o'clock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 o'clock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 o'clock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 o'clock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 o'clock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 o'clock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Each of 8 site comparisons had its own P-value and a value of &lt;0.001 was the difference at the most tender sites</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Quality of Sexual Life - Visit 2</title>
        <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by averaged scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
        <time_frame>Visit 2 (Week 4)</time_frame>
        <population>Averaged scores of Sexual Function Questionnaire at Visit 2 scoring from the prior 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Saline</title>
            <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
          </group>
          <group group_id="O2">
            <title>Topical Liquid Lidocaine</title>
            <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Quality of Sexual Life - Visit 2</title>
          <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by averaged scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
          <population>Averaged scores of Sexual Function Questionnaire at Visit 2 scoring from the prior 30 days.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Desire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="O2" value="16.09" lower_limit="14" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O2" value="11.21" lower_limit="9.71" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Lubrication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="4.18" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Cognitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="5.99" lower_limit="5" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="O2" value="9.05" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" lower_limit="6" upper_limit="9.26"/>
                    <measurement group_id="O2" value="10.50" lower_limit="9.13" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="14" upper_limit="20.54"/>
                    <measurement group_id="O2" value="19.36" lower_limit="17.07" upper_limit="22.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.62" lower_limit="8" upper_limit="10"/>
                    <measurement group_id="O2" value="8.68" lower_limit="8" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Quality of Sexual Life - Visit 3</title>
        <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by average scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
        <time_frame>Visit 3 (End of Study)</time_frame>
        <population>Averaged scores of Sexual Function Questionnaire at Visit 1 scoring from the prior 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Saline</title>
            <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
          </group>
          <group group_id="O2">
            <title>Topical Liquid Lidocaine</title>
            <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Quality of Sexual Life - Visit 3</title>
          <description>To determine whether women's quality of sexual life is improved by use of this local therapy to prevent pain with intercourse. Measured by average scores on the Sexual Function Questionnaire. There are 8 domains measured in the Sexual Function Questionnaire each asking for a score for the prior 30 days: Desire (score range 5-31; ≥23 considered normal function), Arousal-sensation (score range 4-20; ≥14 considered normal function), Arousal-lubrication (score ranges 2-10; ≥8 considered normal function), Arousal-cognitive (score range 2-10; ≥8 considered normal function), Orgasm (score range 1-15; ≥12 considered normal function), Pain (2-15; ≥12 considered normal function), Enjoyment (score range 6-30; ≥23 considered normal function) and Partner (score range 2-10; ≥8 considered normal function).</description>
          <population>Averaged scores of Sexual Function Questionnaire at Visit 1 scoring from the prior 30 days.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Desire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.79" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O2" value="18.32" lower_limit="16" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Sensation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.89" lower_limit="8" upper_limit="13"/>
                    <measurement group_id="O2" value="13.15" lower_limit="11" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Lubrication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal Cognitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="O2" value="7.05" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" lower_limit="1" upper_limit="11"/>
                    <measurement group_id="O2" value="9.5" lower_limit="7" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.18" lower_limit="10.35" upper_limit="12"/>
                    <measurement group_id="O2" value="11.67" lower_limit="9.5" upper_limit="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Enjoyment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.90" lower_limit="17.44" upper_limit="24.44"/>
                    <measurement group_id="O2" value="22.51" lower_limit="21.2" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" lower_limit="8" upper_limit="10"/>
                    <measurement group_id="O2" value="9.36" lower_limit="9" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 hour</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Topical Liquid Lidocaine</title>
          <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
        </group>
        <group group_id="E2">
          <title>Topical Saline</title>
          <description>Topical liquid lidocaine: Comparison of topical liquid lidocaine to placebo on application to the vulvar vestibule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Martha Goetsch</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>503-494-3666</phone>
      <email>whru@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

